FIELD: medicine, pharmaceutics.
SUBSTANCE: described are dosed forms of guanfacine for per oral application, suitable for single intake per day, which has acceptable general size of pills.
EFFECT: dosed form by invention ensures satisfactory pharmacological profile for prolonged delivery of guanfacine during period of time up to 24 hours with regulated total weight of dosed form.
79 cl, 1 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION OF SLOW RELEASE, CONTAINING APLINDOR AND ITS DERIVATIVES | 2004 |
|
RU2376988C2 |
| COMPOSITION COMPRISING HYDROCORTISONE | 2014 |
|
RU2664678C2 |
| IMMEDIATE RELEASE DOSAGE FORM | 2020 |
|
RU2795085C2 |
| COMPOSITION CONTAINING SOLID DISPERSION OF BAZEDOXIFENE ACETATE | 2005 |
|
RU2400227C2 |
| REDUCTION OF INPATIENT VARIABILITY OF LEVODOPA CONCENTRATIONS IN BLOOD PLASMA | 2013 |
|
RU2682681C2 |
| INCREASE OF DRUG BIDOSTASTICITY AT THERAPY BY NALTREXONE | 2011 |
|
RU2640561C2 |
| INCREASE IN BIOAVAILABILITY OF DRUGS IN THERAPY WITH NALTREXONE | 2011 |
|
RU2781141C2 |
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| LEVODOPA FORMULATIONS FOR RAPID RELIEF OF PARKINSON'S DISEASE | 2013 |
|
RU2685718C2 |
| GASTRO-RESISTANT DOSAGE FORMS FOR ORAL ADMINISTRATION WITH CONTROLLED RELEASE | 2018 |
|
RU2812901C2 |
